Bristol Myers Squibb Signs US$1.1 B Metastatic Cancer Pact with Volastra
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 3 (Table of Contents)
Published: 23 Mar-2022
DOI: 10.3833/pdr.v2022.i3.2680 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Bristol Myers Squibb and Volastra Therapeutics have entered into a drug discovery collaboration to leverage the latter’s technology platform to discover and develop new oncology drug candidates...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS